<?xml version="1.0" encoding="UTF-8"?>
<p>Lopinavir is an antiretroviral protease inhibitor used in combination with ritonavir to treat patients with AIDS and HIV infection. Lopinavir is a potent and highly specific inhibitor of HIV‐1 protease. Ritonavir inhibits the metabolism of lopinavir, therefore coadministration of lopinavir and ritonavir in healthy volunteers increases the area under the lopinavir plasma concentration‐time curve&gt; 100‐fold (Hurst &amp; Faulds, 
 <xref rid="jcp29785-bib-0026" ref-type="ref">2000</xref>). In a study by Cao et al. (
 <xref rid="jcp29785-bib-0010" ref-type="ref">2020</xref>), the effect of lopinavir plus ritonavir on adult patients with COVID‐19 in China showed that concomitant use of these drugs had no advantage over standard care and would be approved or rejected in future trials. The reason for choosing this drug together was its therapeutic experience at SARS‐CoV in 2003, which became the drug of choice (Cao et al., 
 <xref rid="jcp29785-bib-0010" ref-type="ref">2020</xref>).
</p>
